公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C. | Annals of Oncology | 39 | 36 | |
2015 | Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014) | CHIUN HSU ; BANG-BIN CHEN ; CHIEN-HUNG CHEN ; MING-CHIH HO ; CHIA-HSIEN CHENG ; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG | Liver Cancer | 17 | 22 | |
2013 | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) | Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG | Liver International | 69 | 60 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
2019 | Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population | CHING-HUNG LIN ; Yap Y.S.; Lee K.-H.; Im S.-A.; Naito Y.; Yeo W.; Ueno T.; Kwong A.; Li H.; Huang S.-M.; Leung R.; Han W.; Tan B.; Hu F.-C.; CHIUN-SHENG HUANG ; ANN-LII CHENG ; YEN-SHEN LU ; Asian Breast Cancer Cooperative Group | Journal of the National Cancer Institute | 81 | 73 | |
2021 | Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling | SUNG-HSIN KUO ; SHIH-HUNG YANG ; Wei, Ming-Feng; Lee, Hsiao-Wei; YU-WEN TIEN ; ANN-LII CHENG ; KUN-HUEI YEH | Cancer cell international | 3 | 3 | |
2022 | Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy | Lau, George; Yu, Ming-Lung; Wong, Grace; Thompson, Alexander; Ghazinian, Hasmik; Hou, Jin-Lin; Piratvisuth, Teerha; Jia, Ji-Dong; Mizokami, Masashi; Cheng, Gregory; Chen, Guo-Feng; Liu, Zhen-Wen; Baatarkhuu, Oidov; ANN-LII CHENG ; Ng, Woon Leung; Lau, Patrick; Mok, Tony; Chang, Jer-Ming; Hamid, Saeed; Dokmeci, A Kadir; Gani, Rino A; Payawal, Diana A; Chow, Pierce; Park, Joong-Won; Strasser, Simone I; Mohamed, Rosmawaiti; Win, Khin Maung; Tanwandee, Tawesak; Sarin, Shiv Kumar; Omata, Masao | Hepatology international | 0 | 0 | |
2019 | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) | Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. | British Journal of Cancer | 2 | 2 | |
2017 | Corrigendum to “Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells” [Neoplasia (United States) 14 (2012) 463–475](S1476558612801023)(10.1596/neo.12300) | Lin Y.-C.; Wu M.-H.; TZU-TANG WEI ; Chuang S.-H.; Chen K.-F.; ANN-LII CHENG ; CHING-CHOW CHEN | Neoplasia (United States) | 0 | 0 | |
2018 | Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026)) | Bruix J.; ANN-LII CHENG ; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. | Journal of Hepatology | 6 | 4 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 1 | 1 | |
2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 0 | 1 | |
2020 | Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection | Tsou H.-H.; HUNG-CHIH YANG ; Hsiao C.-F; Hsiung C.A; Liu T.-W; Chuang M.-H; Wu H.-Y; Hsu Y.-T; Tsui C.-W; PEI-JER CHEN ; ANN-LII CHENG ; CHIUN HSU ; Taiwan Cooperative Oncology Group | Journal of the Formosan Medical Association | 8 | 8 | |
2019 | CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer | KUO-HSING CHEN ; LIANG-IN LIN ; LI-HUI TSENG ; Lin, Yu-Lin; JAU-YU LIAU ; JIA-HUEI TSAI ; JIN-TUNG LIANG ; BEEN-REN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Oncology | 6 | 4 | |
2012 | A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression | YING-CHUN SHEN ; CHIUN HSU ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Oncology | 34 | 29 | |
2000 | Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis | Chuang S.E.; Kuo M.L.; CHIH-HUNG HSU ; Chen C.R.; Lin J.K.; Lai G.M.; CHANG-YAO HSIEH ; ANN-LII CHENG | Carcinogenesis | 240 | 210 | |
2022 | Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma | SUNG-HSIN KUO ; KUN-HUEI YEH ; CHUNG-WU LIN ; JYH-MING LIOU ; MING-SHIANG WU ; Chen, Li-Tzong; ANN-LII CHENG | Cancers | 9 | 8 | |
1992 | Cutaneous angiocentric T-cell lymphoma associated with Epstein-Barr virus | TSEN-FANG TSAI ; Su I.-J.; Lu Y.-C.; ANN-LII CHENG ; Yeh H.-P.; Hsieh H.-C.; HWEI-FANG TIEN ; JAU-SHIUH CHEN ; Uen W.-C. | Journal of the American Academy of Dermatology | 57 | 54 | |
1993 | Cutaneous manifestations of Epstein-Barr virus—associated T-cell lymphoma | Su I.-J.; TSEN-FANG TSAI ; ANN-LII CHENG ; Chen C.-C. | Journal of the American Academy of Dermatology | 64 | 57 | |
1990 | Cutaneous manifestations of postthymic T cell malignancies: Description of five clinicopathologic subtypes | Su I.-J.; Wu Y.-C.; YAO-CHANG CHEN ; Hsieh H.-C.; ANN-LII CHENG ; Wang C.-H.; Kadin M.E. | Journal of the American Academy of Dermatology | 39 | 35 | |